Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Re-induction of a Systemic Immune Response After Initial Response With Immune Therapy With Single-dose Radiotherapy in Metastatic or Locally Recurrent Lung Cancer: A Prospective Phase II Trial (Re-Induce 2)

NCT06024941 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.

NCT NCT06024941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06024941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Re-induction of a Systemic Immune Response After Initial Response With Immune Therapy With Single-dose Radiotherapy in Metastatic or Locally Recurrent Lung Cancer: A Prospective Phase II Trial (Re-Induce 2)
Lead sponsor
Maastricht Radiation Oncology
Phase
Phase 2
Overall status
Withdrawn
Start date
December 1, 2024
Completion date
December 1, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer stage iv